Targovax ASA News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

21.05.21	Targovax to present at upcoming investor and scientific conferences (PR Newswire)
21.05.21	Targovax to present at upcoming investor and scientific conferences (PR Newswire)
06.05.21	Targovax ASA: First quarter 2021 results (PR Newswire)
06.05.21	Targovax ASA: First quarter 2021 results (PR Newswire)
04.03.21	Targovax ASA: Registration of share capital increase following exercise of options (PR Newswire)
04.03.21	Targovax ASA: Registration of share capital increase following exercise of options (PR Newswire)
01.03.21	Targovax ASA: Exercise of options under LTI program and resolution to increase the share capital (PR Newswire)
01.03.21	Targovax ASA: Exercise of options under LTI program and resolution to increase the share capital (PR Newswire)
23.02.21	Continued survival benefit in Targovax's ONCOS-102 trial in mesothelioma at the 21-month follow-up (PR Newswire)
18.02.21	Reminder: Invitation to Targovax's Capital Markets Day 18 February 2021 (PR Newswire)
18.02.21	Reminder: Invitation to Targovax's Capital Markets Day 18 February 2021 (PR Newswire)
15.02.21	Targovax receives Fast-Track designation for ONCOS-102 (PR Newswire)
15.02.21	Targovax receives Fast-Track designation for ONCOS-102 (PR Newswire)
11.02.21	Agenda for Targovax's Capital Markets Day 18 February 2021 (PR Newswire)
11.02.21	Agenda for Targovax's Capital Markets Day 18 February 2021 (PR Newswire)
10.02.21	Targovax and Papyrus Therapeutics enter research collaboration to develop novel ONCOS viruses with receptor tyrosine kinase (RTK) inhibitor functionality (PR Newswire)
10.02.21	Targovax and Papyrus Therapeutics enter research collaboration to develop novel ONCOS viruses with receptor tyrosine kinase (RTK) inhibitor functionality (PR Newswire)
06.01.21	Targovax grants IOVaxis 3 months extension to the exclusive license option for TG mutant RAS vaccines in Greater China and Singapore (PR Newswire)
06.01.21	Targovax grants IOVaxis 3 months extension to the exclusive license option for TG mutant RAS vaccines in Greater China and Singapore (PR Newswire)
15.12.20	Targovax ASA: Save the date - Capital Markets Day 2021 (PR Newswire)
15.12.20	Targovax ASA: Save the date - Capital Markets Day 2021 (PR Newswire)
02.12.20	Targovax ASA: Invitation to online presentation at 10:00 CET 2 December (PR Newswire)
02.12.20	Targovax ASA: Invitation to online presentation at 10:00 CET 2 December (PR Newswire)
02.12.20	Targovax announces impressive objective responses as well as effects on non-injected lesions in ONCOS-102 trial in anti-PD1 refractory melanoma patients (PR Newswire)
02.12.20	Targovax announces impressive objective responses as well as effects on non-injected lesions in ONCOS-102 trial in anti-PD1 refractory melanoma patients (PR Newswire)
24.11.20	Targovax demonstrates encouraging survival data for ONCOS-102 in mesothelioma (PR Newswire)
24.11.20	Targovax demonstrates encouraging survival data for ONCOS-102 in mesothelioma (PR Newswire)
17.11.20	Targovax to present at Bryan Garnier & Co Virtual European Healthcare Conference (PR Newswire)
09.11.20	Targovax announces poster at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting (PR Newswire)
05.11.20	Targovax ASA: third quarter 2020 results (PR Newswire)
05.11.20	Targovax ASA: third quarter 2020 results (PR Newswire)
28.10.20	Targovax announces formation of new Scientific Advisory Board (PR Newswire)
28.10.20	Targovax announces formation of new Scientific Advisory Board (PR Newswire)
19.10.20	Targovax announces accepted abstract at SITC (PR Newswire)
19.10.20	Targovax announces accepted abstract at SITC (PR Newswire)
13.10.20	Targovax announces that the ONCOS-102 and durvalumab trial successfully completes part 1 in colorectal cancer (PR Newswire)
13.10.20	Targovax announces that the ONCOS-102 and durvalumab trial successfully completes part 1 in colorectal cancer (PR Newswire)
12.10.20	Targovax granted European Patent for ONCOS-102 in combination with checkpoint inhibitors (PR Newswire)
12.10.20	Targovax granted European Patent for ONCOS-102 in combination with checkpoint inhibitors (PR Newswire)
22.06.20	Targovax's ONCOS-102 Mesothelioma 12-month Data Powerfully Demonstrate Broad Immune Activation Linked to Clinical Benefit (PR Newswire)
04.06.20	Targovax Enters Collaboration With Leidos to add Checkpoint Inhibitor Functionality to ONCOS Viruses (PR Newswire)
04.06.20	Targovax Enters Collaboration With Leidos to add Checkpoint Inhibitor Functionality to ONCOS Viruses (PR Newswire)
14.05.20	Targovax Announces That the ONCOS-102 and Durvalumab Abstract is Selected for a Poster Discussion Session at ASCO (PR Newswire)
14.05.20	Targovax Announces That the ONCOS-102 and Durvalumab Abstract is Selected for a Poster Discussion Session at ASCO (PR Newswire)
06.05.20	Targovax Announces That Abstract on Interim Phase I Clinical Data From the Phase I/II Peritoneal Trial is Accepted at ASCO (PR Newswire)
06.05.20	Targovax Announces That Abstract on Interim Phase I Clinical Data From the Phase I/II Peritoneal Trial is Accepted at ASCO (PR Newswire)
04.05.20	Targovax Releases Update for Mesothelioma Trial Combining ONCOS-102 and Chemotherapy (PR Newswire)
04.05.20	Targovax Releases Update for Mesothelioma Trial Combining ONCOS-102 and Chemotherapy (PR Newswire)
30.04.20	Targovax ASA Appoints Dr Victor Levitsky as Chief Scientific Officer (PR Newswire)
30.04.20	Targovax ASA Appoints Dr Victor Levitsky as Chief Scientific Officer (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Lonza Grp	535.20	0.79 %	K V
Part Grp Hldg	1’256.00	0.40 %	K V
Novartis	92.29	0.39 %	K V
Alcon	77.88	0.33 %	K V
Holcim	88.54	0.14 %	K V
Swiss Life Hldg	715.80	-0.50 %	K V
UBS Group	27.56	-0.72 %	K V
ABB	49.16	-0.77 %	K V
Sika	226.10	-1.09 %	K V
Logitech Intl	70.88	-1.53 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Targovax ASA

Aktien Top/Flop

Meistgelesene Nachrichten